IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
Open Access
- 11 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Objective: Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) belong to inflammatory rheumatic diseases, the group of conditions of unknown etiology. However, a strong genetic component in their pathogenesis has been well established. A dysregulation of cytokine networks plays an important role in the development of inflammatory arthritis. Interleukin 33 (IL-33) is a recently identified member of the IL-1 family. To date, the significance of IL-33 in inflammatory arthritis has been poorly studied. This research aimed to investigate the potential of IL-33 gene polymorphisms to serve as biomarkers for disease susceptibility and TNF inhibitor response in RA, AS, and PsA patients.Materials and Methods: In total, 735 patients diagnosed with RA, AS, and PsA and 229 healthy individuals were enrolled in the study. Genotyping for three single nucleotide polymorphisms (SNPs) within the IL-33 gene, namely, rs16924159 (A/G), rs10975519 (T/C), and rs7044343 (C/T), was performed using polymerase chain reaction amplification employing LightSNiP assays.Results: In the present study, the IL-33 rs10975519 CC genotype was associated with a decreased risk of developing RA in females, while the IL-33 rs16924159 polymorphism was associated with the efficacy of anti-TNF therapy and clinical parameters for RA and AS patients. The IL-33 rs16924159 AA genotype correlated with higher disease activity and worse clinical outcomes in RA patients treated with TNF inhibitors, and AS patients carrying the IL-33 rs16924159 AA genotype had higher disease activity and a worse response to anti-TNF therapy. That indicates a deleterious role of the IL-33 rs16924159 AA genotype in the context of RA, as well as AS.Conclusions: The obtained results suggest that IL-33 gene polymorphisms might be potential candidate biomarkers of disease susceptibility and anti-TNF treatment response in patients with inflammatory rheumatic diseases.Funding Information
- Narodowe Centrum Nauki
This publication has 80 references indexed in Scilit:
- Hierarchical, imbalanced pro-inflammatory cytokine networks govern the pathogenesis of chronic arthropathiesOsteoarthritis and Cartilage, 2018
- Interleukin‐33 (IL‐33): A nuclear cytokine from the IL‐1 familyImmunological Reviews, 2017
- IL‐33: biological properties, functions, and roles in airway diseaseImmunological Reviews, 2017
- The ST2/IL-33 Axis in Immune Cells during Inflammatory DiseasesFrontiers in Immunology, 2017
- Selected cytokine pathways in rheumatoid arthritisSeminars in Immunopathology, 2017
- The danger from within: alarmins in arthritisNature Reviews Rheumatology, 2016
- Alarmin’ Immunologists: IL-33 as a Putative Target for Modulating T Cell-Dependent ResponsesFrontiers in Immunology, 2015
- The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1Proceedings of the National Academy of Sciences of the United States of America, 2009
- The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’?PLOS ONE, 2008
- IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factorin vivoProceedings of the National Academy of Sciences of the United States of America, 2007